Experimental drug shows promise for sight-stealing eye condition

January 19, 2017 by Steven Reinberg, Healthday Reporter
Compared with controls, the incidence of retinal detachment was significantly less in AXT107- injected or aflibercept-injected eyes. This tiny peptide may form the basis of a new generation of drugs that augment current approaches to macular degeneration and diabetic retinopathy. Credit: e Silva et al., Science Translational Medicine (2017)

An experimental drug may one day make treatment simpler for patients suffering from vision-threatening age-related macular degeneration, researchers say.

So far, the drug—called AXT107—has been only tested on mice and rabbits, but it requires far fewer injections than current therapy to prevent . Current treatment requires frequent injections directly into the eye.

"We anticipate of AXT107 in humans may have a substantially longer effect than current treatment," said lead researcher Dr. Peter Campochiaro. He's a professor of ophthalmology at Johns Hopkins University in Baltimore.

"Instead of eye injections every four to six weeks, we hope it would be several months between injections," he said.

The drug test in rabbits lasted only two months, but the drug appeared both safe and effective, Campochiaro said.

Researchers hope to start the first human trials later this year. This phase 1 trial would test the safety of the drug in people, but further tests would be required to see how effective it is, Campochiaro said.

Research with animals does not always produce similar results in people.

Age-related macular degeneration is a common eye condition and a leading cause of vision loss among people age 60 and older, according to the U.S. National Institutes of Health.

The condition causes damage to the macula, a small spot near the center of the retina and the part of the eye needed for sharp vision.

In some people, age-related macular degeneration advances so slowly that vision loss doesn't occur for a long time. In others, the disease progresses faster and may lead to a loss of vision in one or both eyes, according to the NIH.

As age-related macular degeneration progresses, a blurred area near the center of vision is a common symptom. Over time, the blurred area may grow larger and blank spots may develop in central vision. Objects also may not appear as bright as they used to.

Age-related macular degeneration by itself doesn't lead to complete blindness, the NIH says. The loss of can, however, interfere with simple activities, such as the ability to see faces, drive, cook, read and write.

One type of this condition is known as "wet" or neovascular age-related macular degeneration. This type develops when new blood vessels form and leak fluid and blood into the eye, causing swelling and damage, according to the NIH.

Treatments for this type of macular degeneration have limited effectiveness and require monthly injections directly into the eye to prevent irreversible vision loss, Campochiaro explained.

But the injections of AXT107 in animals lasted twice as long as the usual drugs, such as aflibercept (Eylea). Aflibercept prevents blood vessel growth by blocking a protein called vascular endothelial growth factor (VEGF).

AXT107 also targets VEGF and three other factors that promote , Campochiaro said.

Moreover, AXT107 forms a gel within the eye, which allows it to be released over several months, reducing the number of eye injections patients need to control the disease, he said.

"AXT107 may provide a way to get as good or better effects as patients are getting with current treatment, but with fewer visits and injections," Campochiaro said.

The report was published Jan. 18 in the journal Science Translational Medicine.

One eye specialist not involved with the study said the frequency of current treatments can be a problem.

"Patients with are flooding our offices with multiple injections," said Dr. Mark Fromer, an ophthalmologist at Lenox Hill Hospital in New York City.

"We need treatments that last longer, because you have 60- to 80-year-old patients, it's almost impossible for them to come to the office every month. They do it, but it's rough," Fromer said.

The less a patient has to come to the doctor's office, the better the compliance, he said.

"If they can come in five or six times a year, it is much better for patient compliance and may also result in better care," Fromer said. "Anything we can do to reduce patient visits is a plus."

Explore further: Clinical trial tests cord-blood cells to treat macular degeneration

More information: "Tyrosine kinase blocking collagen IV–derived peptide suppresses ocular neovascularization and vascular leakage," Science Translational Medicine, stm.sciencemag.org/lookup/doi/ … scitranslmed.aai8030

Related Stories

Clinical trial tests cord-blood cells to treat macular degeneration

July 20, 2016
UIC is part of a national phase 2 clinical trial to evaluate the safety and tolerability of using cells derived from multipotent umbilical cord cells to treat age-related macular degeneration, the most common cause of vision ...

Research points to promising treatment for macular degeneration

September 10, 2013
(Medical Xpress)—Researchers at the University of North Carolina School of Medicine today published exciting new findings in the hunt for a better treatment for macular degeneration. In studies using mice, a class of drugs ...

Mouse studies advance treatment for common eye diseases

September 3, 2014
Working with mice, a multicenter team of researchers has found a new way to reduce the abnormal blood vessel growth and leakage in the eye that accompany some eye diseases. The finding could lead to the development of new ...

Age-related macular degeneration treatment works even with other eye problem

November 11, 2012
The primary treatment for wet macular degeneration, a chronic eye condition that causes vision loss, is effective even if patients have macular traction problems, a Mayo Clinic study shows. The findings will be presented ...

Positive clinical trial results on gene transfer to treat macular degeneration

October 20, 2016
The long-term safety of gene transfer to treat neovascular age-related macular degeneration (NVAMD), and the production of two therapeutic proteins encoded by those genes for at least 2.5 years in the eyes of patients with ...

Patients with AMD may not need monthly injections

May 6, 2014
Researchers have found that, contrary to prvious clinical trial findings, monthly injections to counteract age-related macular degeneration (AMD) may not be necessary. The research is being presented at the 2014 Annual Meeting ...

Recommended for you

Glaucoma study finds brain fights to preserve vision

February 23, 2018
A team of researchers, led by David Calkins, Ph.D., vice chair and director of Research at the Vanderbilt Eye Institute, has made a breakthrough discovery in the field of glaucoma showing new hopes for treatments to preserve ...

In effort to treat rare blinding disease, researchers turn stem cells into blood vessels

February 13, 2018
People who inherit a mutated version of the ATF6 gene are born with a malformed or missing fovea, the eye region responsible for sharp, detailed vision. From birth, their vision is severely limited, and there is no cure. ...

Antioxidant therapy prevents devastating vision loss when added to standard-of-care on rare birth defect

February 5, 2018
A new study led by vision researchers at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo and VA Western New York Healthcare System has demonstrated that the addition of widely available ...

Genetic basis for glaucoma uncovered

January 30, 2018
In two recent publications, Northwestern Medicine scientists and international collaborators discovered mutations that cause improper drainage and a buildup of ocular pressure leading to one form of congenital glaucoma, and ...

Study advances gene therapy for glaucoma

January 16, 2018
While testing genes to treat glaucoma by reducing pressure inside the eye, University of Wisconsin-Madison scientists stumbled onto a problem: They had trouble getting efficient gene delivery to the cells that act like drains ...

New study offers added hope for patients awaiting corneal transplants

January 9, 2018
New national research led by Jonathan Lass of Case Western Reserve University School of Medicine has found that corneal donor tissue can be safely stored for 11 days before transplantation surgery to correct eye problems ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.